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In his theory ofidiotypic networks, NielsJerne proposed that antibody variable
regions were organized into a network of complementary and interacting struc-
tures (1). The interconnection between antibodies via idiotypes (Ids) was thought
to pertain not only to the development and maintenance ofthe B cell repertoire
but to regulation of the immune response as well. Numerous studies (2-4) have
now supported the notion that anti-Id antibodies contribute to the regulation of
the immune response. Generally, these studies involved a single, often dominant
Id, rather than a true network ofId connections. However, progress has recently
been made concerning the composition of complex Id networks (5-7) and
idiotypic crossregulation (6, 7).
We have discovered a profound interconnectivity between the acetylcholine
receptor (AChR)' and a-1,3-dextran (DEX) antigen systems. Our results dem-
onstrate a novel idiotypic relationship, whereby an anti-Idfrom the DEX immune
response is an autoantibody against the AChR. Furthermore, because the DEX
determinant is present on certain bacteria (8) (Enterobacter cloacae and Serratia
liquefaciens), there may also be an idiotypic connection between antibody re-
sponses to the AChR and certain bacterial antigens . These findings may provide
information about both the organization of Id networks and the initiation of the
human autoimmune disease myasthenia gravis (MG), which is caused by auto-
antibodies against the AChR (9, 10).
Production ofmAbs
Materials and Methods
mAbs were produced according to previously published methods (11). The antibodies
used in these studies and some of their relevant properties are shown in Table I.
Enzyme-linked Immunoabsorbent Assays (ELISA)
Direct binding assay. This ELISA has been described elsewhere (12). For these studies,
the mAbs were coated ontopolyvinyl microtiter plates ata concentration of4,ug/ml. The
purified antibodies were tested for binding at a concentration of 25-30 Ug/ml. In some
cases, 100 Al of culture fluid supernatant were used. Plates were developed using the
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TABLE I
Source and Specificity of mAbs
* The specificity of the mAbs refers to the original antigen binding detected in the
initial ELISA screening ofthe fusion. As reported in this paper, some ofthese mAbs
were subsequently found to also bind to other antigens.
appropriate combination of isotype-specific second antibodies labeled with alkaline phos-
phatase. The minimum value considered positive here was an A405 >0.200 above the
control value obtained with the same antibody tested against BSA.
Inhibition assay.
￿
For this ELISA, DEX-BSA was coated onto microtiter plates at a
concentration of 4 jug/ml. Next, varying amounts of the test solutions were added to the
wells (50 wl/well), followed by the addition of 50 Al of purified SRI I or DId (final
concentration 30 Ag/ml). Nigerotriose is a glucose trisaccharlde prepared by Dr. Johnston
and was a gift from Dr. W. Schuler (Munster, Federal Republic of Germany). The initial
concentration of nigerotriose used was 100 jug/ml. DEX was the same as that used to coat
the plates (100 tcg/ml initial concentration). EB5, the anti-Id raised against SRI 1, had an
initial concentration of 50 jug/ml. ACR24 was used at a concentration of 100 pg/ml, as
was J558. Finally, AB 1, which served as a control for EB5, is a 'y1, K mAb derived from
A/J mice immunized with HOPC8. This antibody was also used at an initial concentration
of 50 Ag/ml. The plates were developed by adding either alkaline phosphatase-coupled
anti-human IgM (SRI 1) or anti-human IgG (DId).
Measurement of human serum antibodies.
￿
An ELISA that has been described elsewhere
(13) was used to detect specific serum antibodies. Briefly, microtiter plates were coated
with DEX (4 tag/ml) and blocked with 1 % BSA in borate-saline buffer before addition of
serum. Sera were diluted 1 :40 in BSA borate-saline buffer containing 0.25% Tween 20.
The plates were developed with alkaline phosphatase-coupled second antibodies as above.
DEX B1355S (35% a-1,3 linkages), derived from L. mesenteroides, was a gift from Dr.
Slodki, U.S. Department of Agriculture, Peoria, IL.
Results
The AChR-DEX Network.
￿
The studies described here led to the construction
of an elaborate Id network connecting the immune responses against AChR and
DEX and involving the antibodies displayed in Table I. A summary of these
findings depicting the AChR-DEX network is shown in Figure 1 . CdB3 is a
syngeneic anti-Id mAb produced by immunizing BALB/c mice with the mAb
Sh174, which precipitates rat and human muscle AChR. During the initial
characterization of CdB3, it was found (D. Dwyer, unpublished observations)
that this mAb did not react with a panel of 12 different antibodies, indicating its
specificity for Sh174. Surprisingly, as shown in the left side of Fig. 1, CdB3 also
reacts with EB3, which is a monoclonal anti-Id against the DEX-binding myeloma,
J558 . Although the binding of CdB3 to Sh174 (A405, 0.607) and EB3 (A405,
mAb Isotype Specificity* Source
Sh174 y2b, K AChR BALB/c
CdB3 A, K Sh174 BALB/c
CB6 'U, a EB3 C57B1/6
BA6 F+, K EB3 BALB/c
EB3 yI,K J558 A/J
J558 a, X DEX BALB/c
M104 ~, DEX BALB/c
CD3 yl, J558, M104 A/J
117 A, K CD3 BALB/c
MB5 'y I, K SRII BALB/c
AC3 -Y I, K SRI] BALB/c
EB5 'y I, a SRI] BALB/c
SR11 A, K ACR24 Human
ACR24 - Y I, K AChR BALB/c1312 IDIOTYPIC NETWORK CONNECTIVITY
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FIGURE 1 .
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Summary of the antibody interactions connecting the AChR and DEX immune
responses. The arrows indicate a significant reaction between the antibodies as measured with
an ELISA. Generally, the A4o5 values represented by the arrows were 0.400-1 .200 when the
plates were read 30 min after the addition of substrate.
TABLE II
Binding Specificity ofAnti-Id mAbs
Binding was evaluated with an ELISA and the results have been expressed as the A4o5 obtained after 30 min of
reaction.
0.610) is similar, these two antibodies are not identical because Sh174 does not
bind to J558, and EB3 does not precipitate AChR. Two other mAbs, CB6 and
BA6, derived from fusions of neonatal B cells, were selected in our laboratory
on the basis of their interaction with EB3. In view of the similarities between
EB3 and Sh174, CB6 and BA6 were tested against Sh174. The scheme in Fig. 1
shows that these mAbs also react with Sh174, confirming the idiotypic relation-
ship between Sh174 and EB3.
Representative binding data from some of the key antibodies in this network
are presented in Table 11. Many of the antibodies in Fig. 1, including Sh174,
EB3, CD3, J558, M104, SR 11, and ACR24, have been described elsewhere (14,
15). From Table II it is clear that CdB3 binds to EB3, Sh174, AC3 and EB5,
whereas BA6 recognizes EB3, Sh174 and ACR24. CB6 binds to EB3 and Sh174
only, and 117 binds to EB3, MB5, AC3 and CD3 (to be discussed in more detail
later). These four antibodies were tested against a larger panel of antibodies that
are not shown here and did not react with any others (except 117, which also
bound to AB 1). Because these antibodies did not react with a common epitope
composed of isotypic or allotypic determinants, it can be concluded that they
recognize an epitope in the variable region of these antibodies and can be
considered anti-Ids. Similar crossreactive anti-Ids have been described by other
investigators (5-7).
Absorbance (A,o5) in ELISA with:
mAb EB3
(y1, K)
Sh174
(y26, K)
BPCI
(y26, K)
MB5
(y1, K)
AC3
(y I, K)
EB5
(y I, K)
ACR24
('y1, K)
CD3
(y1,X)
CdB3 0.610 0.607 0.005 0.000 0.258 0.369 0.022 0.038
BA6 0.677 0.224 0.019 0.012 0.057 0.014 0.579 0.025
CB6 0.318 0.223 0.013 0.001 0.000 0.005 0.000 0.008
117 0.788 0.013 0.000 1 .085 1.356 0.070 0.078 0.724DWYER ET AL.
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In addition, the data in Table II show that CdB3, CB6, and BA6, which are
all IgM, are distinct antibodies with unique antigen-binding profiles. CdB3 and
BA6 were derived from BALB/c mice whereas CB6 was obtained from a
C57BL/6 mouse. Furthermore, CdB3 but not CB6 binds to EB5 and AC3 (to
be discussed later), and BA6 alone binds strongly to ACR24. Interestingly, the
binding of some of these anti-Ids, such as CdB3, to Id on the ELISA plate is not
inhibited by soluble Id. However, these anti-Ids do bind to Id on the cell surface
of the hybridoma (D. Dwyer, unpublished observations), and can regulate the
relevant immune response.
The above findings prompted us to search for an idiotypic connection between
the anti-AChR and anti-DEX responses using some of the human antibodies we
have available. SR 1 I is a human mAb obtained from a myasthenic patient. As
described elsewhere (15, 16) this antibody was selected because it bound specif-
ically to ACR24, a mouse mAb directed against AChR from both Narcine
electroplax and mammalian muscle, and not to other murine mAbs. In addition,
it was shown (15) that the binding of SRI I to ACR24 was blocked by antigen
(AChR), further confirming the idiotypic nature of this interaction. We also
reported that serum from certain MG patients contain anti-Ids against ACR24,
which are similar to SRI 1 . These studies showed that, among the serum anti-
bodies from some myasthenics, there is an idiotypic counterpart to the ACR24
mAb. Therefore, SRI 1 and an ACR24 equivalent represent an important part
of the antibody repertoire expressed by patients with MG .
Previously, a panel of murine anti-Id mAbs had been produced (J. Kearney,
unpublished data) which were specific for SRI 1 . EB5, MB5, and AC3 are
members of this panel of anti-Ids. In a separate study (J . Kearney, unpublished
data), a murine mAb (117) derived from a primary anti-DEX response was
selected for further examination because it bound to an anti-Id (CD3) in the
DEX system. Thus, 117 is an anti-(anti-Id) in the DEX immune response, that
has in vivo activity in suppressing the anti-DEX response, presumably by activat-
ing a set of anti-Id B cells (J. Kearney, unpublished observations). As shown in
Fig. 1, the mAb 117 binds not only to CD3 but to EB3, MB5, and AC3 as well.
Furthermore, CdB3, an anti-Id against Sh174, reacts with EB3, as discussed
previously, and with EB5 and AC3 . The binding characteristics of 117 and CdB3
provide additional support for a connection between the immune responses to
DEX and AChR. All other possible combinations of antibody binding (e.g.,
Sh174 vs. J558, MB5 vs. AChR, etc .) were tested, and only those interactions
depicted here were significant, with the exception of the BA6-ACR24 interac-
tion, which was omitted for the sake of clarity, and the BA6-AChR interaction,
which has been reported elsewhere (17). Because BA6 binds both to anti-AChR
antibodies (Sh 174 and ACR24) and to the AChR, it is an epibody as defined by
Bona et al. (18) .
The Id connections described here are largely, but not exclusively, restricted
to the AChR-DEX network. There was little interaction of the antibodies from
Table I with nine equivalent antibodies (Ids, anti-Ids, etc.) from the phospho-
rylcholine antigen system (117 bound to AB 1, an anti-T 15 antibody). However,
some of the antibodies uppermost in our scheme (e .g., BA6 and 117) are more
broadly reactive and are connected with other antigen systems .
The crossreactive anti-Ids, although typically of lower affinity than highly1314
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FIGURE 2.
￿
Binding profiles of monoclonal anti-Ids. An ELISA was used to evaluate the
binding of anti-Ids at various protein concentrations. The results are presented as the Aaos
obtained with a multiscan after 15 minof reaction. Thefollowinginteractions were examined:
FZ1.4-ACR24 (A), EBG3-AChR(A), 117-MB5(o), CdB3-Sh174 (p), 117-CD3 (O), andCdB3-
EB3 (/).
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specific mAbs, nevertheless bind quite strongly to the Id-bearing antibody. These
data are depicted in Fig. 2. Binding profiles are shown for Sh174 and 117, and
for comparison, FZ1.4, which is an anti-Id specific for ACR24, and EBG3, which
reacts with Narcine AChR. These latter two antibodies are high-affinity mAbs
that were obtained by immunization with antigen. As mentioned earlier, 117
was derived from mice immunized with DEX, and yet its affinity for MB5 is very
similar to that of FZIA. The affinity for CD3 is less, but still represents very
effective binding. In contrast, CdB3 was obtained after immunization with
Sh174, and the affinity ofthis interaction is comparable to that ofthe 117-CD3
interaction. The CdB3-EB3 interaction is the weakest of those depicted here,
however, this anti-Id can potently suppress the immune response to DEX at
standard doses of anti-Id (D. Dwyer, unpublished observations), indicating the
physiological relevance ofthis binding.
Binding Pattern ofa Human mAb against DEX.
￿
Based on the scheme in Fig. 1,
it was possible to predict that the human mAb, SRI 1, might bind to DEX and
the results in Fig. 3 confirm this prediction. The data presented here concern
the competitive inhibition of SRI I binding to DEX by various substances
including the mAbsJ558, EB5, and ACR24, and the trisaccharide nigerotriose.
TheJ558 VH is considered a representative BALB/c antibody involved in DEX
binding. J558 effectively competes with SRI I for binding to DEX, suggesting
that these two mAbs are binding to a similar or identical determinant. The anti-
Id EB5 also effectively inhibits bindingofSRI I to DEX, whereas a control mAb,
AB1, does not. Surprisingly, although SRI I binds to ACR24, it is clear from
Fig. 3 that ACR24 does not inhibit binding of SRI 1 to DEX, implying that
recognition of these two molecules is accomplished by different parts of the
SRI 1 variable region. DEX itselfand nigerotriose strongly inhibit the interaction
of SR11 with DEX, confirming the earlier suggestion that a-1,3-glucosidic
linkages are the relevant antigenicdeterminant. Thus, SR11, selected forbinding
to ACR24, binds to DEX as well. As shown here, this recognition is probably
achieved through two different sites because (a) ACR24 does not inhibit bindingtoo
so
zo
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FIGURE 3 .
￿
Inhibition of SRII binding to DEX. Various substances were tested for their
ability to inhibit the binding of SRII to DEX. The results of these assays have been expressed
as the percentage of a control assay where no inhibitor was added. Nigerotriose (*-"), DEX
EB5 (O- - _O), ACR24 (A-"), J558 (0- - -0), AB1 (A-0).
TABLE III
Purified Human Antiidiotypes against ACR24 Bind to DEX
Anti-Id was purified from the serum ofapatient with MG using an ACR24affinity
column. Thecharacterization ofthese antibodies has been described elsewhere (15).
These data were obtained with an ELISA similar to that of Fig. 3.
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to DEX, and (b) nigerotriose does not inhibit binding of SRI I to ACR24 (data
not shown), although it is very effective at inhibiting DEX binding. Finally, SRI I
agglutinates both E. cloacae and S. liquefaciens and reacts with these two bacteria
in an ELISA (data not shown), indicating that this human mAb also recognizes
DEX-like determinants on certain bacteria.
As a further indication of the degree of network connectivity, serum anti-Ids
from a second myasthenic patient, that had previously been purified on an
ACR24 affinity column, also bind strongly to DEX, similar to SRI 1 . These data
appear in Table III . The specificity and binding characteristics of DId have been
described in detail elsewhere (15) . DId binds to ACR24 and to DEX as shown,
and the binding to DEX can be inhibited by nigerotriose. Thus, there is far more
interconnectivity between the AChR and DEX immune responses than would
occur by chance, especially considering the similarities between SRI 1 and DId .
Anti-DEX Antibodies in MG Patients.
￿
If the DEX determinant is an important
epitope involved in the induction ofthe immune response against certain bacteria
and these artibodies elicit the autoimmune response in MG, then there might be
antibodies against DEX in the serum of some myasthenic patients. Therefore,
sera from 60 patients with MG and 40 controls were tested for antibodies against
DEX . The results of this study are shown in Fig. 4 . It is clear that a number of
myasthenic patients (16%) have serum antibodies against DEX. Serum antibody
Antigen Addition A4os
BSA - 0.014
ACR24 - 0.398
DEX - 0.740
DEX Nigerotriose (50,ug/ml) 0.311
DEX Nigerotriose (12.5 Ag/ml) 0.4781316
￿
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FIGURE 4.
￿
Anti-DEX antibody levels in patients with MG. Serum from myasthenic patients
and nonmyasthenic controls were assayed for antibodies against DEX. The control group
included patients with thesuspectedautoimmune diseases multiple sclerosisand Guillain-Barre
syndrome. The results have been expressed as the A4os reading after the subtraction of
background values against BSA-coated wells.
levels are considered positive if they are >3 SD above the mean of the control
values (i.e., >0.106). Analysis of the immunoglobulin isotype of the anti-DEX
antibodies revealed that the response is largely restricted to the IgG class (data
not shown) . Occasionally, low levels of IgM or IgA anti-DEX antibodies were
detected.
Discussion
The data presented here illustrate two important points. The first concerns
idiotypic interconnectivity between different antigen systems. Although implicit
in Jerne's theory, there has been little evidence showing that the immune
responses against disparate antigens are connected via Ids. The Id connections
described so far (19-21) only show shared idiotypy between antibodies against
different antigens, rather than the complex web of Ids constructed in Fig. 1.
Furthermore, we have shown a hierarchical organization of the Id network, in
agreement with earlier predictions (22, 23). Antibodies such as CdB3, 117, and
BA6 are crucial links in the network, and we have termed these antibodies super
organizers. Although super organizer antibodies tend to bind witha loweraffinity
to Ids than conventional highly specific mAbs, this binding is strong enough to
elicit physiological responses (7 and D. Dwyer, unpublished results). These
antibodies are probably similar to the promiscuous mAbs described by Holmberg
et al. (5). The molecular basis for the recognition of shared idiotypy by super
organizers is not clear. Victor-Kobrin et al. have studied similar antibodies, and
they showed that antibodies bearing the crossreactive Id belong to the same VH
gene family (6). Studies to examine this issue are underway.
The second point concerns the induction of autoimmunity via the normal
operation of Id networks. As Plotz (24) suggested, an anti-Id in one response
may be an autoantibody against a different self antigen. In the case of MG,
infection by the common opportunistic pathogens E. cloacae or S. liquefaciensDWYER ET AL.
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may lead to an immune response against DEX-like determinants on the bacteria.
Under certain circumstances, antibodies such as SRI I and DId would be pro-
duced. These anti-DEX antibodies would then trigger an anti-Id response,
typified by antibodies that resemble ACR24, however, these anti-Ids would also
be autoantibodies against the AChR. The anti-AChR response would be ampli-
fied if antibodies like Sh174 were also produced via perturbations of the AChR-
DEX network. Thus, a bacterial infection could initiate MG indirectly by stimu-
lating the production of certain anti-Ids that also happen to be autoantibodies .
Naturally, in addition to bacterial infection, other factors such as theappropriate
immune response genes (HLA-D) and immunoglobulin genes, and T cell abnor-
malities are probably necessary for the induction and development of MG .
The model presented here for the initiation of autoimmunity requires that
there are functional Id connections between different immune responses. Victor-
Kobrin et al. (6) and Kearney and Vakil (7) have already demonstrated cross-
regulation of immune responses via crossreactive anti-Ids. Preliminary data from
our laboratory indicate that CdB3 can suppress the immune responses to both
the AChR and DEX. Therefore, it will be important to determine whether there
is a functional connectivity in the AChR-DEX network.
Summary
Extensive idiotypic connectivity has been discovered between the antibodies
composingthe immune responses against the acetylcholine receptor (AChR) and
a-1,3-dextran. The idiotypic connections form an elaborate network linking
these disparate antigen systems, and there is an hierarchical organization of the
antibodies in this network. Thekey anti-Ids that interconnect these two responses
are more crossreactive, lower-affinity antibodies. Interestingly, 15% of patients
with MG, which is caused by autoantibodies against the AChR, have serum
antibodies against DEX. Control sera are negative for anti-DEX antibodies.
Certain anti-DEX antibodies also bind to anti-AChR antibodies via idiotypic
interactions. These findings suggest a model for the initiation of autoimmunity
in MG. Antibodies made in response to DEX epitopes on the surface of certain
bacteria would elicit the production of anti-Ids. However, some of these anti-Ids
would also be autoantibodies against the AChR . Thus, is some circumstances,
autoimmunity may develop as a consequence of the normal operation of regu-
latory idiotypic networks.
Received for publication 28 April 1986 and in revisedform 7July 1986.
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